title: Cardioprotective effects of erythropoietin on postresuscitation myocardial dysfunction in appropriate therapeutic windows.
abstract: OBJECTIVE
  Erythropoietin has been noted for its cardioprotective effects. The objective of the study is to investigate its effects on postresuscitation myocardial dysfunction and therapeutic windows.
  
  
  METHODS
  Randomized animal study.
  
  
  METHODS
  Animal research laboratory.
  
  
  METHODS
  Adult male adult Wistar rats.
  
  
  METHODS
  Cardiopulmonary resuscitation was started after 6.5 or 9.5 mins of asphyxia-induced cardiac arrest. The resuscitated animals received either erythropoietin (1000, 3000, or 5000 U/kg) or placebo intravenously 3 mins after return of spontaneous circulation.
  
  
  RESULTS
  Erythropoietin treatment improved the 3-day survival and left ventricular dP/dt40 and peak negative dP/dt after 6.5 mins asphyxia-induced cardiac arrest. The cardioprotective effects of erythropoietin decreased after 9.5 mins asphyxia-induced cardiac arrest with worse postresuscitation left ventricular dP/dt40 and peak negative dP/dt (p < .01 for both). The erythropoietin showed a dose-dependent response for its cardioprotective effects. The 3-day survival rates were higher in the group treated with erythropoietin 5000 U/kg than with 3000 and 1000 U/kg groups (p = .045 and .003, respectively). Postresuscitation left ventricular dP/dt40 and peak negative dP/dt were more preserved in the group treated with erythropoietin 5000 U/kg than the groups with lower doses (p < .05 for both).
  
  
  CONCLUSIONS
  Erythropoietin has the potential to improve postresuscitation myocardial dysfunction and short-term survival in appropriate therapeutic windows.
authors.affiliation: Department of Emergency Medicine, National Taiwan University Hospital Yun-Lin Branch, Taiwan, ROC.
authors.forename: Chien-Hua
authors.initials: CH
authors.lastname: Huang
authors.forename: Chiung-Yuan
authors.initials: CY
authors.lastname: Hsu
authors.forename: Min-Shan
authors.initials: MS
authors.lastname: Tsai
authors.forename: Tzung-Dau
authors.initials: TD
authors.lastname: Wang
authors.forename: Wei-Tien
authors.initials: WT
authors.lastname: Chang
authors.forename: Wen-Jone
authors.initials: WJ
authors.lastname: Chen
mesh_terms: D000818:Animals; D002316:Cardiotonic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003326:Coronary Circulation / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004921:Erythropoietin / Q000008:administration & dosage / Q000627:therapeutic use*; D006323:Heart Arrest / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects; D008297:Male; D015428:Myocardial Reperfusion Injury / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D012121:Respiration, Artificial; D013997:Time Factors
chemical_list: D002316:Cardiotonic Agents; D004921:Erythropoietin